Evolus initiates Nuceiva launch in Germany and Austria

Evolus has commenced the commercial launch of Nuceiva or botulinum toxin type A, in Germany and Austria, and is now available for direct order and delivery to customers. Nuceiva is approved by the European Commission for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown , when the severity of the above facial lines has an important psychological impact in adults below 65 years of age2. "We are excited to introduce Nuceiva to customers in Germany and Austria, the second largest aesthetic toxin market in Europe1," said David Moatazedi, President and CEO of Evolus Inc. "Entering this dynamic European market is the latest in a series of geographical expansion milestones that will help fuel Evolus’ above market average growth in the underpenetrated aesthetic neurotoxin market."